Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia

NCT02656173 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02656173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02656173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
January 25, 2016
Completion date
July 21, 2017
Enrollment
568 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder